Antibiotic alternatives are treatments that prevent or manage infections without relying solely on conventional antibiotics. They include vaccines, bacteriophages, antimicrobial peptides, microbiome-based therapies, and measures that reduce infection risk, such as improved diagnostics and infection control. These approaches matter because antimicrobial resistance is already a major health threat: a 2022 analysis in The Lancet estimated that bacterial antimicrobial resistance was directly responsible for 1.27 million deaths worldwide in 2019 and associated with 4.95 million deaths. Alternatives are not a universal replacement for antibiotics, but used appropriately they can help prevent infections, target particular pathogens, and reduce unnecessary antibiotic exposure.
Antibiotic alternatives and the infection-management challenge
The World Health Organization (WHO) defines antimicrobial resistance as the process by which microorganisms no longer respond to medicines that previously treated them. Antibiotic resistance is the bacterial subset of this wider problem. Resistance can arise naturally, but the use and misuse of antimicrobial medicines accelerate its spread. The consequence is not simply that a drug stops working: infections may become harder to treat, require more complex care, and increase the risks of complications and transmission.
“Antibiotic alternatives” is a broad practical category rather than one standardized clinical class. It covers interventions that prevent infection, strengthen or redirect host defenses, selectively attack pathogens, or make existing antibiotics more effective. The choice depends on the infection site, organism, severity, patient, and strength of clinical evidence. In severe or rapidly progressing bacterial infections, proven antibiotics remain essential; alternatives should complement established care, not delay it.
Why alternatives are relevant
The 2019 global estimates published by the Antimicrobial Resistance Collaborators in The Lancet found that bacterial resistance was directly responsible for approximately 1.27 million deaths and associated with approximately 4.95 million deaths. These are global estimates for bacterial antimicrobial resistance, not counts of deaths that alternatives alone could prevent. They nevertheless show why prevention, faster diagnosis, responsible prescribing, and new treatment strategies must work together.
Alternatives are relevant in both human and animal health. Preventing an infection can avert the need for an antibiotic; distinguishing bacterial from viral illness can help avoid treatment that is unlikely to work; and pathogen-specific approaches may offer options when standard treatments fail. The following sections group these strategies by how they manage infection.
Preventive alternatives reduce infection and antibiotic demand
Preventive alternatives reduce the chance of infection or transmission before treatment is needed. WHO’s infection-prevention guidance emphasizes measures such as hand hygiene, sanitation, vaccination, and appropriate infection-control practices in health-care settings. Their shared characteristic is that they reduce exposure or susceptibility rather than directly kill bacteria after an infection is established.
Vaccines and immunization
Vaccines prepare the immune system to recognize a pathogen or its components, helping prevent disease or reduce its severity. By preventing infections, they can also reduce opportunities for antibiotic use. The WHO’s 2024 report on the bacterial vaccines pipeline identifies vaccination as an important tool against antimicrobial resistance, while noting that vaccine development and access vary by pathogen and region.
Vaccines do not treat an active bacterial infection and do not eliminate the need for antibiotics when those medicines are clinically indicated. Their effect is preventive and population-oriented: broad vaccine coverage can reduce disease burden and transmission, while the precise benefit depends on the vaccine, pathogen, uptake, and local epidemiology.
Infection prevention and control
Infection prevention and control (IPC) comprises practical measures that prevent pathogens from spreading in health-care facilities and communities. Examples include hand hygiene, cleaning and disinfection, safe device use, appropriate isolation, and surveillance. WHO’s global IPC work describes these measures as essential to reducing health-care-associated infections and containing resistant organisms.
IPC is not a substitute for treating an infection that has already developed. Instead, it reduces new cases and transmission, protecting patients and staff while lowering avoidable demand for antimicrobial treatment. Its effectiveness depends on reliable supplies, staff training, monitoring, and consistent implementation.
Prevention lowers the number of infections that need treatment, but it cannot eliminate them. For established disease, the next group of alternatives aims to improve the match between a treatment and the pathogen.
Targeted therapies offer pathogen-focused alternatives
Targeted therapies act on particular microbes or microbial processes. Unlike broad-spectrum antibiotics, which can affect many susceptible bacteria, some targeted approaches are designed to focus on a narrower range of pathogens. Their potential advantages include precision and possible usefulness against resistant infections, but their suitability depends on accurate identification, access, safety, and clinical evidence.
Bacteriophage therapy
Bacteriophages, or phages, are viruses that infect bacteria. Phage therapy uses selected phages to attack bacterial pathogens. Because many phages infect only particular bacterial strains, treatment may require matching a phage to the organism causing the infection. Researchers are investigating phages for difficult-to-treat infections, including infections involving antibiotic-resistant bacteria.
Phage therapy is not yet a routine, widely standardized replacement for antibiotics. The U.S. Food and Drug Administration (FDA) describes phage products as investigational in the United States, and clinical use may involve regulatory pathways for individual cases or research. Important challenges include identifying an effective phage, manufacturing consistent products, understanding interactions with the immune system, and generating robust clinical-trial evidence.
Antimicrobial peptides and other novel agents
Antimicrobial peptides are short molecules that can damage microbes or interfere with their functions. Some occur naturally as part of immune defenses; others are being developed or modified as candidate medicines. Researchers are also exploring agents such as anti-virulence compounds, which aim to disrupt a pathogen’s ability to cause disease rather than simply kill it.
These approaches remain at different stages of development. Potential benefits must be weighed against practical barriers, including toxicity, stability, delivery to the infection site, cost, and the possibility that microbes will evolve resistance. A promising laboratory result does not establish that a treatment is safe or effective in patients; clinical testing is required.
Microbiome-based therapies
The microbiome is the community of microorganisms living in and on the body. Microbiome-based therapies seek to restore or alter these communities so they can resist harmful organisms or support health. A notable clinical example is fecal microbiota-based treatment for recurrent Clostridioides difficile infection, in which disrupted gut microbial communities can allow the pathogen to proliferate.
In the United States, the FDA approved two microbiota-based products in 2022 for preventing recurrence of C. difficile infection in adults after antibacterial treatment for recurrent infection. These products are specific medical interventions, not general-purpose probiotics. Their indications, screening requirements, and potential risks differ from ordinary dietary supplements, so use should follow clinical guidance and product labeling.
Targeted therapies can be powerful but are not always immediately available or appropriate. Better diagnostics help determine whether an infection is bacterial, identify its cause, and select the safest effective treatment.
Diagnostics and stewardship make treatment more precise
Diagnostic and stewardship approaches do not necessarily kill pathogens themselves. They help ensure that treatment is used when needed and is suited to the infection. The U.S. Centers for Disease Control and Prevention (CDC) describes antibiotic stewardship as a coordinated effort to improve and measure how antibiotics are prescribed and used, with the goals of optimizing treatment and limiting avoidable harm.
Rapid and point-of-care diagnostics
Rapid diagnostics are tests designed to provide clinically useful information faster than conventional workflows. Depending on the test, they can help distinguish viral from bacterial illness, identify a pathogen, or detect resistance markers. Results can guide decisions about whether to prescribe an antibiotic, which medicine to choose, or whether further testing is needed.
A test is useful only when its accuracy, timing, and results are interpreted in context. A negative result may not rule out infection, and detecting a microorganism does not always prove that it is causing the patient’s symptoms. The CDC’s Core Elements of Hospital Antibiotic Stewardship Programs therefore support pairing diagnostic information with clinical assessment, laboratory expertise, and timely review of therapy.
Antibiotic stewardship and responsible prescribing
Antibiotic stewardship means improving antibiotic decisions so patients receive the right medicine, dose, route, and duration when treatment is warranted. It includes avoiding antibiotics for viral infections, reviewing prescriptions as test results emerge, and choosing the narrowest effective option when appropriate. Stewardship does not mean withholding necessary treatment; it seeks to protect patients from both undertreatment and unnecessary exposure.
The CDC’s outpatient stewardship guidance notes that at least 28% of antibiotics prescribed in U.S. outpatient settings are unnecessary, based on its analysis of prescribing data. This figure applies to the U.S. outpatient context and should not be generalized to every country or care setting. It illustrates why diagnostic support and careful prescribing can be meaningful complements to new medicines.
Combining strategies in practice
In practice, infection management often combines several approaches: vaccination and IPC to prevent disease, diagnostic testing to clarify its cause, and an evidence-based treatment selected for the patient. For example, a hospital may use infection-control precautions to limit transmission of a resistant organism, obtain cultures to identify the pathogen, and adjust antimicrobial therapy when susceptibility results become available. If a patient has recurrent C. difficile infection, clinicians may consider an approved microbiota-based product after appropriate antibacterial treatment, according to the relevant indication and guidance.
These examples show why alternatives are best understood as part of a treatment system rather than as a single replacement drug. Each intervention has a distinct role, and the evidence, risks, and regulatory status should be evaluated individually.
Conclusion: antibiotic alternatives complement effective care
Antibiotic alternatives include preventive measures such as vaccines and infection control, targeted approaches such as phages and microbiome-based therapies, and decision-support strategies such as rapid diagnostics and antibiotic stewardship. The scale of bacterial antimicrobial resistance—estimated to have directly caused 1.27 million deaths globally in 2019—underscores the need to develop these options and use existing treatments responsibly.
No single alternative can manage every infection, and many emerging therapies still need stronger evidence, broader access, or further regulatory review. Patients should not stop or replace prescribed antibiotics without consulting a qualified clinician. Health systems can support progress by strengthening vaccination and IPC, expanding timely diagnostics, improving stewardship, and investing in carefully designed clinical research. For further reading, consult WHO guidance on antimicrobial resistance and infection prevention, CDC stewardship resources, and FDA information on approved or investigational therapies.
Sources: World Health Organization, Antimicrobial resistance, https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance; Antimicrobial Resistance Collaborators, “Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis,” The Lancet, 2022, https://doi.org/10.1016/S0140-6736(21)02724-0; World Health Organization, Bacterial vaccines in clinical and preclinical development: an overview and analysis, 2024, https://www.who.int/publications/i/item/9789240093897; World Health Organization, Infection prevention and control, https://www.who.int/health-topics/infection-prevention-and-control; U.S. Food and Drug Administration, Consumer Alert on Regenerative Medicine Products Including Stem Cell and Exosome Products, and information on bacteriophage therapy, https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products; U.S. Food and Drug Administration, FDA Approves First Fecal Microbiota Product, https://www.fda.gov/news-events/press-announcements/fda-approves-first-fecal-microbiota-product; U.S. Food and Drug Administration, FDA Approves Second Fecal Microbiota Product for Prevention of Recurrence of Clostridioides difficile Infection, https://www.fda.gov/news-events/press-announcements/fda-approves-second-fecal-microbiota-product-prevention-recurrence-clostridioides-difficile; U.S. Centers for Disease Control and Prevention, Core Elements of Hospital Antibiotic Stewardship Programs, https://www.cdc.gov/antibiotic-use/hcp/core-elements/hospital.html; U.S. Centers for Disease Control and Prevention, Core Elements of Outpatient Antibiotic Stewardship, https://www.cdc.gov/antibiotic-use/hcp/core-elements/outpatient-antibiotic-stewardship.html.
